Leijun Hu

TL;DR: The humanised monoclonal antibody LY2495655 (LY) as discussed by the authors was used to test whether LY increases appendicular lean body mass and improves physical performance in older individuals who have had recent falls and low muscle strength and power.

TL;DR: Treatment of postmenopausal women with an antibody targeted against sclerostin resulted in substantial increases in spine and hip BMD, and further study of blosozumab as a potential anabolic therapy for osteoporosis is supported.

TL;DR: Findings support the continued study of blosozumab as an anabolic therapy for treatment of osteoporosis and anti‐drug antibodies generally declined in patients who had detectable levels during prior treatment.

TL;DR: In this article, a humanized monoclonal antibody to myostatin was used to treat skeletal muscle wasting in advanced cancer patients, which is a prevalent and not readily managed condition.